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Abstract
Background: Metastatic colon cancer is one of the leading causes of cancer-related death worldwide, with disease
progression and metastatic spread being closely associated with angiogenesis. We investigated whether an
antiangiogenic gene transfer approach using the Sleeping Beauty (SB) transposon system could be used to inhibit
growth of colorectal tumors metastatic to the liver.
Results: Liver CT26 tumor-bearing mice were hydrodynamically injected with different doses of a plasmid
containing a transposon encoding an angiostatin-endostatin fusion gene (Statin AE) along with varying amounts of
SB transposase-encoding plasmid. Animals that were injected with a low dose (10 μg) of Statin AE transposon
plasmid showed a significant decrease in tumor formation only when co-injected with SB transposase-encoding
plasmid, while for animals injected with a higher dose (25 μg) of Statin AE transposon, co-injection of SB
transposase-encoding plasmid did not significantly affect tumor load. For animals injected with 10 μg Statin AE
transposon plasmid, the number of tumor nodules was inversely proportional to the amount of co-injected SB
plasmid. Suppression of metastases was further evident in histological analyses, in which untreated animals showed
higher levels of tumor cell proliferation and tumor vascularization than animals treated with low dose transposon
plasmid.
Conclusion: These results demonstrate that hepatic colorectal metastases can be reduced using antiangiogenic
transposons, and provide evidence for the importance of the transposition process in mediating suppression of
these tumors.
Background
Carcinoma of the colon is the second most common
cause of cancer-related death in the United States and
other developed countries [1]. The primary cause of
mortality is dissemination of the disease to secondary
sites, with the liver being the primary, and most critical,
organ for development of metastasis [2,3]. Liver resec-
tion is the only effective treatment to facilitate a poten-
tial cure. However, less than 10% of patients are eligible
for surgery, since they present with advanced or disse-
minated disease due to the absence of early diagnostic
symptoms [2-4].
Tumor neovascularization plays a critical role in color-
ectal cancer progression, and increased angiogenesis has
been associated with poor prognosis and relapse of color-
ectal disease [5,6]. There are several small molecule inhibi-
tors of angiogenesis currently in clinical trials [7]. The
anti-VEGF antiangiogenic antibody bevacizumab is now
used clinically as a first line treatment in combination with
standard first and second-line chemotherapy regimens for
treatment of metastatic colorectal cancer, conferring a sig-
nificant increase in survival time (20-25 months) [8,9].
However, antiangiogenic factors have a cytostatic rather
than cytotoxic effect, therefore requiring continuous and
possibly lifelong administration of the recombinant pro-
tein [10,11]. Introduction of sequences encoding antian-
giogenic gene products is an alternate approach to achieve
continuous and sustained expression of angiostatic factors
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angiogenesis.
Both viral and non-viral vector systems have been
tested for potential therapeutic gene transfer against col-
orectal cancer. Viral vectors have been used by most
investigators for gene delivery, due to the higher effi-
ciency of gene transfer compared to non-viral systems.
Viral vector types that have been used to deliver antian-
giogenic genes for therapy of colorectal cancer include
adenoviral vectors [12-15] and adeno-associated viral
(AAV) vectors [16], and non-viral vectors include HVJ
cationic liposomes and naked plasmid DNA. HVJ-catio-
nic liposomes were shown to be effective in inhibiting
angiogenesis by repeat intratumoral injections of vector
encoding mouse macrophage metalloelastase in a subcu-
taneous model of colorectal cancer [17]. Uesato et al
expressed angiostatin and en d o s t a t i ni ns u b c u t a n e o u s
tumors after repeated low-voltage electroporation and
achieved decreased tumor growth [18]. More recently,
Wen et al reported hydrodynamic plasmid injection to
express NK4 in a hepatic model of liver metastasis, with
successful inhibition of tumor formation [19,20]. Non-
viral anti-angiogenic gene delivery has thus, been used
successfully, with therapeutic benefits in inhibiting the
growth of colorectal tumors, but the duration of effec-
tiveness is constrained by the transient period of gene
expression.
The Sleeping Beauty (SB) transposon system combines
the advantages of non-viral plasmid-based vector sys-
tems with the integrative capabilities of some viral vec-
tors. This plasmid-based vector system provides
prolonged expression of the transgene through integra-
tion into the host chromosome, thereby circumventing
the need for repeated administration of the therapeutic
gene [21]. The SB transposon system has been success-
fully used to transfer genes into a variety of cell types
[22-25], including neoplastic tissue [26-28]. This system
consists of 2 components; a transposon, comprising a
gene of interest flanked by indirect repeat sequences,
and the synthetic SB transposase, which catalyzes exci-
sion and integration of the gene into genomic DNA.
I nt h ep r e s e n ts t u d y ,t h eS Bt r a n s p o s o ns y s t e mw a s
used to achieve transfer of antiangiogenic genes into
tumor-bearing animals. We investigated the antitumor
effects of a transposon vector that encodes an angiosta-
tin-endostatin fusion gene (Statin AE), administered in a
CT26 mouse model of colorectal cancer metastatic to
the liver. Statin AE transposon administration was asso-
ciated with a significant antitumor effect as gauged by
inhibition of tumor growth, and reduction in tumor vas-
culature. A dose-dependent requirement for SB transpo-
sase-encoding plasmid at lower doses of Statin AE
transposon was observed, implicating the importance of
transposition and stable Statin AE expression in low
substrate (transposon) conditions such as those likely to
be achieved in large animals or humans. These results
demonstrate the potential effectiveness of the SB trans-
poson system for therapeutic antiangiogenic gene trans-
fer in metastatic colorectal cancer.
Results
Hepatic Gene Delivery and Localization of Gene
Expression
There have been several studies reported in which vec-
tors containing either angiostatin or endostatin resulted
in significant tumor regression upon administration to
tumor bearing mice. In addition, combined treatment of
tumor bearing mice with vectors encoding both angios-
tatin and endostatin resulted in an additive effect in
tumor growth inhibition when compared to treatment
using either of these agents alone [29-31]. The StatinAE
gene, which is a fusion of murine angiostatin and endo-
statin genes, has been demonstrated to confer significant
inhibition of subcutaneously implanted human glioblas-
toma and melanoma xenografts [27,32]. We therefore
constructed a Sleeping Beauty transposon plasmid con-
taining the StatinAE and firefly luciferase genes regulated
by a bidirectional promoter (pKT2/BidEAL, Figure 1A).
In this construct a luciferase transgene is transcription-
ally regulated by the phosphoglycerate kinase (PGK) pro-
moter, while in the opposite orientation a CpG free
enhancer/elongation factor 1-alpha (EF1-a)p r o m o t e r
regulates expression of an angiostatin-endostatin fusion
g e n e[ 3 2 ] .T of o r mt h et r a n s p o s o n ,t h et r a n s c r i p t i o n a l
cassettes are flanked by Sleeping Beauty T2 transposon
inverted terminal repeats [33].
Murine CT26 colon carcinoma is a transplantable
tumor that shows strong hypervascularization and is an
effective model for evaluation of an angiostatic, antitu-
mor approach. Balb/c mice were injected with CT26
colorectal tumor cells intrasplenically, subsequently
allowing the cells to seed into the liver and initiate loca-
lized tumor growth. Two days following tumor seeding,
animals were hydrodynamically injected (see Materials
and Methods) with 10 μg (low dose) or 25 μg( h i g h
dose) of pKT2/BidAEL along with either 0, 5, 10, 12.5
or 25 μg of SB transposase plasmid. Plasmid delivery to
the liver was assessed by in vivo bioluminescence ima-
ging of luciferase expression at 24 hours, 1 week and
two weeks post-injection. Figure 1B depicts a represen-
tative animal with localized hepatic expression of luci-
ferase imaged at 24 hours after plasmid injection. Levels
of expression in the high dose and low dose transposon
groups are depicted in Figures 2A and 2B respectively.
All animals, regardless of presence or absence of SB
plasmid, showed similar levels of expression, with the
highest levels observed at 24 hours and 1 week post-
injection, ranging from 6 × 10
9 to 5 × 10
10 photons/sec.
Belur et al. Molecular Cancer 2011, 10:14
http://www.molecular-cancer.com/content/10/1/14
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markedly reduced to levels that were approximately
1000-fold lower (mean of 1.2 × 10
7 photons/sec). Levels
of luciferase expression in both the high and low dose
transposon groups were similar, and both groups exhib-
ited a similar time course of expression over two weeks.
These results confirm hepatic delivery and subsequent
transgene expression of the therapeutic pKT2/BidAEL
plasmid.
Effect of antiangiogenic transposon gene therapy on
tumor load
Animals were sacrificed 21 days after tumor infusion, and
the effect of antiangiogenic transposon treatment on tumor
burden was gauged by total liver weight (Figures 3A and
3B) as well as reduction of the number of tumor metas-
tases (Figures 4A and 4B). The mean liver weight of
untreated tumor bearing animals (4.2 +/- 2.1 g) was signifi-
cantly higher (P < 0.01) than that of each of the groups of
antiangiogenic transposon-treated tumor bearing animals,
in which the mean weights ranged from 1.37 to 1.65 g, as
well as the non-tumor bearing control group, which had a
mean liver weight of 0.9 g. There was no significant differ-
ence in liver weights between groups that were co-injected
with either 0, 12.5, or 25 μgo fS Bt r a n s p o s a s ep l a s m i d
along with 25 μg of Statin AE transposon or between any
of these groups and the non-tumor bearing control group
(Figure 3A).
Figure 1 Gene delivery and expression of firefly luciferase in the liver. A, Plasmid constructs used in gene delivery to the liver. PGK,
phosphoglycerate kinase; pA, SV40 polyadenylation signal; SB11, Sleeping Beauty 11 transposase gene; EF1-a, elongation factor1-a; E, CpG-free
synthetic enhancer; inverted arrowheads, T2 transposon inverted repeats. B, Representative mouse from the group that received 10 μg
transposon and 10 μg SB plasmids showing gene delivery and expression in the liver 24 hrs following hydrodynamic gene delivery.
Figure 2 Time course and levels of luciferase expression following hydrodynamic gene delivery. Animals were injected with plasmids as
indicated below, and imaged at various time points for in vivo luciferase gene expression (mean +/- positive SD). A,2 5μg high dose
transposon plasmid; B,1 0μg low dose transposon plasmid.
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dose (10 μg) Statin AE transposon plasmid alone had a
mean liver weight of 3.75 +/- 0.43 g, which was not sig-
nificantly lower than that of the untreated tumor-bearing
control group (4.4 +/- 2.4 g). However, animals that were
co-injected with either 5, 10, or 25 μg of SB transposase
plasmid had mean liver weights ranging from 1.4 +/-
0 . 3gt o1 . 8+ / -0 . 7ga n dt h e s ew e r es i g n i f i c a n t l yl o w e r
(P < 0.0005) than untreated tumor-bearing control ani-
mals and tumor-bearing animals administered 10 μg
transposon plasmid alone (Figure 3B).
In all groups of animals treated with a high dose
(25 μg) of Statin AE transposon DNA, there was a sig-
nificant reduction in the number of liver tumor nodules
in comparison with that of untreated tumor bearing ani-
mals (P < 0.05), whether or not SB transposase plasmid
Figure 3 Decrease in liver weights following antiangiogenic transposon gene therapy. Animals were sacrificed 21 days post-tumor
injection, livers were extracted and weighed, to gauge effect of treatment on tumor load (mean +/- SD). Transposon (pKT2/BidAEL), and
transposase (pPGKSB11) plasmid DNA amounts infused into animals are summarized below the bar graph. A,2 5μg high dose transposon
plasmid; B,1 0μg low dose transposon plasmid. *P < 0.05; **P < 0.005, ***P < 0.0005.
Figure 4 Effects of antiangiogenic transposon gene therapy on liver metastases. Livers were extracted from sacrificed animals and tumor
nodules on the liver were enumerated. Transposon (pKT2/BidAEL), and transposase (pPGKSB11) plasmid DNA amounts infused into animals are
summarized below the graph. A,2 5μg high dose transposon plasmid (bar indicates mean of n = 3-4); B,1 0μg low dose transposon plasmid,
(bar indicates mean of n = 8). *P < 0.05; ***P < 0.0005.
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similar regardless of dosage of SB transposase.(12.5 or 25
μg). However, in animals treated with a low dose (10 μg)
of Statin AE transposon alone (Figure 4B), antitumor
effectiveness was observed only in animals co-adminis-
tered SB transposase-encoding DNA. Infusion of 10 μg
Statin AE transposon alone caused only a minimal (non-
significant) reduction in liver tumor nodules compared
to untreated tumor-bearing animals. In contrast, there
was a significant decrease in metastases (P < 0.0001)
observed in animals co-infused with 5 μg (36 +/- 29), 10
μg( 1 9+ / -2 0 ) ,o r2 5μg (14 +/- 12) SB plasmid, i.e a
trend toward decreased nodule formation with increasing
doses of SB transposase plasmid.
Effect of antiangiogenic transposon treatment on
histological indices of metastatic tumors
To evaluate the effect of anti-angiogenic gene therapy,
animals were sacrificed at 3 weeks post-injection and
livers were analyzed histologically for the presence and
extent of replacement of normal liver by tumor tissue.
Livers of untreated tumor bearing mice were enlarged
and contained multiple, coalescing pale nodules that
replaced nearly all of the normal hepatic parenchyma
(Figure 5A), while the livers of animals treated with Sta-
tin AE transposon plasmid were smaller in size and con-
tained tumor nodules that replaced a much lower
volume of tissue (Figure 5B).
The hepatic replacement area (HRA) (defined as the
percentage of normal hepatic tissue that has been dis-
placed by metastatic tumor) was assessed morphometri-
cally in histological sections for the low dose transposon
mice, and is summarized in Figure 5C. In untreated
tumor bearing controls, the hepatic replacement area
was close to 100% in all 3 mice examined (i.e. there was
essentially no normal liver tissue detectable in these ani-
mals). Animals treated with low dose transposon alone
had a mean HRA of 68.3%, and animals that received
various doses of SB plasmid had mean HRAs ranging
from 12.83 to 35.26%. The group that received 10 μgo f
SB transposase plasmid was the only group that differed
significantly from untreated controls. Despite the strik-
ing means, the lack of significant difference observed for
the other treated groups was probably due to low sam-
ple size and variability among samples.
Effect of antiangiogenic transposon gene therapy on
tumor endothelium and proliferation of colorectal
cancer cells
Tumors were evaluated for the effect of low dose Statin
AE transposon treatment on proliferation of tumor cells
and on tumor vascularization by histomorphometric eva-
luation of serial immunohistochemistry sections using
antibodies directed against Ki67 and CD31, respectively
(Figure 6A, B, and 6C). The highest level of tumor cell
proliferation (9.6%) was observed in the tumor bearing
untreated group, with significantly lower mean prolifera-
tion indices (2.6-4.8%) seen in animals that received Statin
AE transposon plasmid with or without SB transposase
plasmid (Figure 6B). Similarly, tumor tissues from tumor
bearing untreated mice had the highest index of CD31
positive blood vessels (9%). In comparison, animals that
were treated with Statin AE transposon plasmid with or
without SB transposase plasmid demonstrated significantly
lower mean (3-3.5%) of vessel density (Figure 6C). There
was no significant difference between animals treated with
vs. without SB transposase plasmid for either Ki67 or
CD31 preparations.
Extended survival of tumor-bearing mice treated with
antiangiogenic transposon
An additional cohort of tumor bearing animals was
tested to determine the effect of SB transposase plus sta-
tin AE transposon administration on survival. Animals
were implanted with 5 × 10
4 tumor cells intrasplenically
as described in Materials and Methods and then 3 days
later, injected hydrodynamically with 10 μgS A Et r a n s -
poson with or without 25 μg SB11 transposase plasmid.
The animals were imaged weekly, demonstrating high
level luciferase expression and verifying effective hydro-
dynamic gene delivery (data not shown). All untreated
animals, as well as animals treated with transposon
alone, succumbed to tumor and were euthanized by day
22 and 23 respectively (Figure 7). In contrast, survival
was significantly extended (p < 0.0001), to day 40 in
some cases, for animals that were treated with both
transposon and transposase encoding plasmids. Tumor
burden was evaluated at time of sacrifice, verifying the
growth of hepatic metastases (not shown). We conclude
that inhibition of CT26 tumor growth brought about by
coinfusion of SAE transposon plus SB transposase
encoding plasmid confers increased survival in tumor-
bearing animals.
Discussion
StatinAE gene transfer using a Sleeping Beauty transposon
vector resulted in antitumoral effects in an animal model of
colorectal cancer metastatic to the liver. Significant tumor
growth inhibition was seen in mice injected with a high (25
μg) dose of antiangiogenic transposon plasmid, in which
co-injection of the SB transposase did not achieve any
further tumor regression. In contrast, antitumor activity of
the Statin AE transposon administered at a lower dose
(10 μg) was dependent on co-infusion of SB transposase-
encoding plasmid. These results suggest that antiangiogenic
gene therapy using the SB non-viral transposon system has
the potential to be an effective treatment for colorectal
cancer metastatic to the liver, and that this process is
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dose-limiting conditions.
Although antiangiogenic proteins show great promise
in preclinical cancer models, their effectiveness in the
clinic, especially when administered alone, has been lim-
ited [34-36]. The effect of VEGF on tumor and vasculari-
zation has been studied by many groups, demonstrating
it’s pivotal role in increasing vascular permeability, tumor
growth and metastasis [37,38]. In pre-clinical studies,
VEGF targeting strategies have demonstrated significant
antivascular effects and tumor growth inhibition.
Although several drugs and small molecule inhibitors of
VEGF are being clinically tested, their efficacy as mono-
therapeutic agents in advanced stage disease has been
discouraging, due to short half-lives and dose limiting
toxicities [39]. However, there is a significant survival
benefit when VEGF-targeted therapy is combined with
standard chemotherapy for metastatic colorectal cancer
[36]. Also, most inhibitors of angiogenesis exert their
effect against newly formed blood vessels rather than
existing vasculature. The inability of these agents to com-
pletely eradicate disease presents a serious challenge for
patients with advanced malignant tumors. For most
angiogenesis inhibitors, tumor growth resumes after ces-
sation of therapy [39]. This necessitates administration of
high doses and prolonged treatment with antiangiogenic
proteins to obtain a sustained therapeutic effect.
Delivery of gene sequences encoding recombinant
inhibitors of angiogenesis potentially allows for localized
and sustained expression, which could reduce the risk of
systemic toxicity and perhaps increase efficacy. Other
advantages include the possibility of expressing multiple
antiangiogenic gene products that act via different
mechanisms, thereby increasing the effectiveness of the
Figure 5 Effects of transposon antiangiogenic therapy on macroscopic appearance and tumor hepatic replacement area (HRA) of
resected livers. Livers from sacrificed animals were evaluated macroscopically for clinical appearance, and histologically, for replacement of
hepatic tissue by tumor tissue. Transposon (pKT2/BidAEL), and transposase (pPGKSB11) plasmid DNA amounts infused into animals are
summarized below the graph. A, Liver from untreated tumor bearing control animal; B, Liver from animal treated with 10 μg low dose
transposon + 25 μg SB transposase; C, % HRA in cohorts of animals treated with low dose of transposon plasmid (bar indicates mean of n = 3
per group). *P < 0.05.
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sequences encoding endogenous anti-angiogenic pro-
teins endostatin and angiostatin have been characterized
in several studies, and their synergistic effects when
used in combination (either in individual or separate
vectors) is well documented [29-31,40]. We therefore
investigated an angiostatin-endostatin fusion protein
previously shown to confer potent antitumor effects in a
subcutaneous melanoma model in vivo [32].
The integrating Sleeping Beauty (SB) transposon system
circumvents the primary limitation of non-viral plasmid
based gene transfer, i.e. the transient duration of gene
expression that fails to give way to long-term expression.
SB-mediated transposition has been shown to occur in a
variety of cultured cell types, in zebrafish [41] and mouse
embryos and germ cells [42], in human primary blood
lymphocytes [26], and in mouse somatic tissues, including
the lung and the liver [25,43-46]. SB-mediated transposi-
tion in mouse liver has been verified in several laboratories
by recovery and sequencing of transposon-chromosome
junction sequences [22,25,44,47-52].
SB has also been used successfully to deliver antitu-
mor genes to neoplastic tissue. Ohlfest et al successfully
used the SB transposon system to deliver a cocktail of
antiangiogenic genes to human glioblastoma xenografts
in mice, subsequently observing increased survival and
sustained regression of tumor [27]. Wu et al compared
the efficacy of interferon-gamma immunogene therapy
using non-integrating plasmid vectors vs SB plasmid
vectors in a syngeneic glioma model. Only animals
co-injected with SB transposase plasmid exhibited pro-
longed expression of interferon-gamma and a significant
increase in survival (3 weeks), while expression in ani-
mals treated with transposon plasmid alone was unde-
tectable after 1 week [53].
While hydrodynamic tail vein injection has been used
very effectively for delivering DNA to liver tissue in
rodents, extending this technique to humans is still
Figure 6 Immunohistochemical analysis of tumor tissues for cell proliferation and tumor vasculature. A, IHC staining to determine tumor
vasculature and proliferation was performed in 5 μm sections on liver. Samples from animals treated with 10 μg transposon plasmid and varying
amounts of transposase plasmids were stained using anti-CD31 (tumor vasculature) and anti-Ki67 antibodies (tumor proliferation) and visualized
by light microscopy. B, Percent positively staining area using Ki67 antibody; C, Percent positively staining area using CD31 antibody. Percentage
of positively stained areas in respective groups was determined by measuring the area of immunopositivity vs. total tissue area in each of 10
random fields (mean +/- SD). Transposon (pKT2/BidAEL), and transposase (pPGKSB11) plasmid DNA amounts infused into animals are
summarized below the graph. *P < 0.05; **P < 0.005.
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the use of balloon occlusion catheters for successful
gene delivery to the liver in large animals. Delivery of
DNA into occluded rabbit liver under X-ray guidance
[54], into the left lateral lobe of pig liver by catheteriza-
tion and occlusion of the portal vein [55], and to the
whole liver of pig and dog via the inferior vena cava
(IVC) with double balloon occlusion above and below
the IVC-hepatic vein conjunctions [56,57] have been
reported. Liu et al have developed a device that uses
high pressure from a gas cylinder and a computer-
controlled switch to drive and regulate DNA injection
in pigs [58]. Use of this device, combined with vessel
occlusion and image guided catheterization to achieve
site specificity, was found to provide effective gene deliv-
ery [59]. Overall, these results from large animal studies
demonstrate that modifications of the hydrodynamic
technique can potentially be applied to humans.
Our results demonstrate that animals injected with both
transposon and transposase-encoding plasmids survive
significantly longer than untreated control animals, or ani-
mals treated with transposon plasmid alone. However,
transgene expression declines over time, leading to even-
tual emergence of tumor metastases. Transgene-specific
immune responses, both humoral and cell-mediated, have
been described. Aronovich et al have shown that pro-
longed expression of ß-glucuronidase after SB transposon-
mediated delivery elicited an immune response against
transgene-expressing cells, which were subsequently elimi-
nated (22). Lutzko et al have characterized humoral
immune responses against transgene products by ELISA,
and have demonstrated cellular immune responses using
lymphocyte proliferation assays [60]. Relative persistence
of transgene expression is also mouse-strain dependant.
Injection of recombinant adenovirus expressing human
alpha-1-antitrypsin (hAAT), resulted in persistent, circu-
lating levels of hAAT in C57Bl/6 mice, while Balb/c mice
Figure 7 Survival of mice treated with antiangiogenic transposon. The Kaplan-Meier plot shows the fraction of animals surviving vs. time
after implantation of CT26 cells at day 0 with subsequent hydrodynamic injection of SAE transposon with or without SB transposase-encoding
plasmid on day 3 (8 mice per group). Differences in survival between groups was evaluated by log-rank analysis. *P < 0.005.
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al have shown that hydrodynamic injection of CpG
replete, supercoiled human Factor IX encoding plasmid in
Balb/c mice resulted in loss of transgene expression after
3-4 weeks, while therapeutic levels of Factor IX expression
were maintained in mice that received CpG depleted plas-
mid [62]. Any or all of these factors could account for the
decline in gene expression observed in our study. Modula-
tion or counteraction of the immune response is therefore
essential in maintaining sustained transgene expression
and continued suppression of tumor metastases.
Here, we have shown that the SB transposon system
can be used to successfully deliver antiangiogenic genes
and inhibit colorectal tumors metastatic to the liver. We
observed that treatment with a high dose of antiangio-
genic transposon plasmid appeared to be effective with
no requirement for co-delivery of SB transposase. How-
ever, antitumor effectiveness of Statin-AE transposon
when administered at low dose (10 μg) was dependent
on SB transposase. Since transposon delivery in large
animals and in humans is likely to be infrequent, the
low dose treatment is considered to be more representa-
tive of the low level of gene transfer that is to be
expected in a clinical setting. In this case, co-delivery of
the SB transposase encoding plasmid is required,
thereby enabling sustained expression of the therapeutic
antiangiogenic transgene through transposition, and
thus continued inhibition of tumor growth.
Conclusions
Patients who would benefit the most from antiangiogenic
gene therapy may be those with early metastatic disease
or even preoperative or perioperative disease [10,11]. In
this study, we have shown significant inhibition of liver
metastases using the SB transposon system. However,
complete eradication of tumor was not seen in any of the
treated groups. Clinically, antiangiogenic gene therapy
may be most well suited for use as an adjuvant therapy
when administered along with existing treatment options
of surgery and/or chemotherapy [8,9]. This combination
therapy may facilitate the use of low dose chemotherapy
in patients. Future preclinical studies will evaluate trans-
position and animal survival in combination therapy of
SB with other cytoreductive treatments.
Methods
Plasmids and cell lines
T h em u r i n eC T 2 6c o l o nc a r c i n o m ac e l ll i n e( A T C C ,
Manassas, VA) was routinely maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin/fungizone. SB transposon
and transposase containing plasmids were constructed
using standard molecular cloning techniques. The trans-
poson plasmid containing the bidirectional promoter
(pKT2/LuBiG) is described in Multhaup et al [63]. Statin
A Ew a sc l o n e da sa nEcoRI-NotIf r a g m e n tf r o mp T 2 /
CAE [27] into plasmid pKT2/PGCL to generate plasmid
pKT2/BidAEL. The SB transposase plasmid pPGK-SB11
consists of the phosphoglycerate kinase promoter regu-
lating transcription of the SB11 transposase as described
previously [49].
Establishment of hepatic tumors
Female Balb/c mice (6-8 weeks of age) were obtained from
NIH (Frederick, MD) and maintained under specific
pathogen-free conditions. All animals were treated accord-
ing to the NIH Guidelines for Animal Care with approval
o ft h eI A C U Co ft h eU n i v e r s i t yo fM i n n e s o t a .E x p o n e n -
tially growing CT26 colon carcinoma cells were harvested
by trypsinization, suspended in Hanks’ balanced salt solu-
tion, and 1 × 10
5 viable cells (as determined by trypan
blue exclusion) in a total volume of 200 μl were injected
intraspenically as previously described [64]. Briefly, ani-
mals were administered 0.2 ml of an anaesthetization
cocktail consisting of ketamine HCl (8 mg/ml; Phoenix
Scientific, St. Joseph, MO), acepromazine maleate (0.1 mg/
ml; Phoenix Scientific), and butorphanol tartarate
(0.01 mg/ml; Fort Dodge Animal Health, Overland Park,
KS). A peritoneal incision was made to expose the spleen.
Cells were delivered directly to the spleens of recipient
animals, and a sterile cotton tip applicator was used to
apply pressure over the injection site for 3 minutes.
A splenectomy was subsequently performed to remove the
primary site of tumor inoculation, thus confining tumor
formation to the liver. The incision was closed with staples
and the animal allowed to recover.
Hydrodynamic delivery of transposon and transposase
encoding plasmids
3 days following tumor cell implantation, 8 animals per
experimental group were weighed and administered
0.03 ml of an anaesthetization cocktail as described
above. Lactated Ringers solution was added to plasmid
DNA to bring the total volume (in mL) equivalent to 10%
of the total body weight (in grams) for each mouse. The
plasmid DNA solution was then injected rapidly through
the tail vein of the animal in a period of 4-8 seconds.
Animals that did not receive the injection in less than
8 seconds were omitted from the study. Injected animals
were placed on a heating pad and monitored until recov-
ery from anesthesia [65].
In vivo luciferase imaging
Animals were anaesthetized using a sedative dose
(400 μl i.p. for a 25 gram mouse) of the anaesthetization
cocktail described above, followed by intraperitoneal
injection of 100 μl of luciferin substrate (28.5 mg/ml;
Caliper Life Sciences, Hopkington, MA). Five minutes
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Page 9 of 12following luciferin injection, mice were imaged for
1 second, using an intensified CCD camera (Xenogen
Corporation, Alameda, CA). Raw values were recorded
as photons of light emitted per second [66].
Animal necropsy and immunohistochemistry
Animals were sacrificed 21 days post-tumor seeding,
or at the time of declining health in the survival
study. Animals were euthanized according to the Uni-
versity of Minnesota IACUC-approved protocols. The
date of euthanasia was recorded as the end day of sur-
vival and autopsy was subsequently performed. Liver
weights and tumor nodule counts were recorded.
Intact livers from all groups except the nontumor
bearing control group were snap frozen in 2-methyl-
b u t a n ea n ds t o r e di nl i q u i dn i t r o g e n .F r o z e nt i s s u e
blocks were sectioned at 5 microns, mounted on slides
a n ds t o r e da t- 8 0 ° Cu n t i lu s e ,a tw h i c ht i m et h e yw e r e
allowed to come to room temperature, fixed in acet-
one for 10 min, and either stained routinely with
hematoxylin and eosin or immunostained using anti-
bodies directed against CD-31 or Ki67. For this proce-
dure, endogenous peroxidase activity was blocked with
0.3% H2O2 for 15 minutes. Undiluted avidin and bio-
tin were applied for 15 minutes each to block non-
specific biotin (DAKO X0590). In addition a protein
serum block was applied for 15 minutes. The appro-
priate primary antibody (rat anti-mouse CD 31; BD
Pharmingen Cat #550274 or rat anti-mouse Ki-67;
Dako Cat # M7249) was applied at a dilution of 1:100
(CD31) or 1:25 (Ki-67) for 60 minutes. The secondary
antibody (biotinylated anti-rat 1:300; Vector Labora-
tories Cat # BA-4001) was applied for 30 minutes fol-
l o w e db yu n d i l u t e ds t r e p t a v i d i n - H R P( D a k oC a t#
K1016). The brown reaction product was detected
using 3,3’diamino-benzidine (Dako Cat # K3466). Sec-
tions were counterstained with Mayer’s hematoxylin.
For negative control sections, normal rat serum was
substituted for the primary antibody.
Histomorphometry
The H&E stained tissue sections were imaged using a
1× objective and the immunohistochemical sections
were imaged using a 20× objective. The 1× images were
captured with a Nikon E800 microscope and a Nikon
DXM 1200 digital camera (Nikon Instruments Inc.,
Tokyo, Japan) and included the entire area of tissue.
The 20× images were captured with an Olympus BX40
(Olympus, USA) and a SPOT Insight digital camera
(Diagnostic Instruments Inc., Sterling Heights, IL) and
were taken only within tumor tissue. Measurement of
images (1X) of the H&E stained sections were used for
morphometric evaluation of % tumor area using Image-
Pro Plus 6.2 (Media Cybernetics, Silver Springs,
Maryland). Tumor area (%) was determined by tracing
the outer margin of each metastatic lesion and deter-
mining its area, summing the areas of all metastatic
lesions in the tissue section, and dividing this sum by
the total area of the tissue section.
Images of the immunohistochemistry sections were
analyzed using Image-Pro Plus 6.2 (Media Cybernetics,
Silver Springs, Maryland). Areas within the tumors that
stained positively for Ki-67 or CD31 by IHC were differ-
entiated from negative areas by using the threshold
command. 5 randomly selected fields (field size approxi-
mately 265,350 square microns) from tumor tissue in
each section were evaluated. The total area of tissue as
well as the area of immunopositivity for CD-31 or
Ki-67, respectively, were measured (μm
2). The area of
immunopositivity was then recorded as a percentage of
the total area. Results from the 5 fields were then aver-
aged for each section.
Statistical analysis
Data were analyzed using GraphPad Prizm 5.0 software
(GraphPad Software Inc., San Diego, CA). Statistical
analysis of differences between groups was determined
using one way analysis of variance (ANOVA), with
Tukey’s post test analysis. Animal survival was evaluated
by the Kaplan-Meier product limit method, comparing
differences among animal groups by the log rank test.
Differences were considered significant when P < 0.05
for ANOVA.
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